Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock.
June 6, 2023
· 4 min read